The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 1.14M shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 72.23% since April 14, 2016 and is uptrending. It has outperformed by 67.54% the S&P500.
The move comes after 7 months positive chart setup for the $2.11 billion company. It was reported on Nov, 16 by Barchart.com. We have $62.95 PT which if reached, will make NASDAQ:SRPT worth $1.22 billion more.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. RBC Capital Markets upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Monday, September 19. RBC Capital Markets has “Outperform” rating and $83 price target. Cowen & Co maintained the shares of SRPT in a report on Wednesday, August 26 with “Hold” rating. The firm earned “Overweight” rating on Monday, August 24 by Piper Jaffray. The rating was maintained by Jefferies with “Hold” on Tuesday, April 26. The rating was maintained by Robert W. Baird with “Outperform” on Monday, September 19. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Outperform” rating by RBC Capital Markets on Wednesday, August 26. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Equal-Weight” rating given on Thursday, October 27 by Morgan Stanley. The firm has “Neutral” rating by Piper Jaffray given on Friday, January 15. Wedbush maintained the shares of SRPT in a report on Monday, October 10 with “Outperform” rating. The firm earned “Hold” rating on Monday, September 19 by Jefferies.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.32, from 0.84 in 2016Q1. The ratio improved, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 1,063 shares. Blackrock Advsrs holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 142,806 shares. Teacher Retirement Of Texas accumulated 6,034 shares or 0% of the stock. Deutsche National Bank Ag, a Germany-based fund reported 445,308 shares. Pointstate Cap Ltd Partnership reported 150,000 shares or 0.06% of all its holdings. Blackrock owns 77,227 shares or 0% of their US portfolio. Fincl Architects holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 505 shares. Brown Brothers Harriman And, a New York-based fund reported 32,000 shares. Moreover, Amici Cap Lc has 0.09% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 25,000 shares. Creative Planning, a Kansas-based fund reported 65,700 shares. Moreover, Legal & General Gp Public Ltd Liability Corp has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 7,192 shares. Proshare Advsrs Lc holds 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 39,296 shares. Seven Eight Limited Com owns 25,302 shares or 0.17% of their US portfolio. Columbia Wanger Asset Ltd Limited Liability Company has 641,932 shares for 0.14% of their US portfolio. Credit Suisse Ag has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT).
Insider Transactions: Since September 14, 2016, the stock had 0 insider purchases, and 8 selling transactions for $8.94 million net activity. 24,557 Sarepta Therapeutics Inc (NASDAQ:SRPT) shares with value of $736,710 were sold by Kaye Edward M. MD. 7,000 shares were sold by Howton David T, worth $420,000 on Thursday, September 22. Aphale Jayant sold $1.75M worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, September 19. Mahatme Sandesh also sold $1.50M worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares. Shares for $438,660 were sold by Ruff Shamim.
Another recent and important Sarepta Therapeutics Inc (NASDAQ:SRPT) news was published by Profitconfidential.com which published an article titled: “Sarepta Therapeutics Inc: $40.00 Is Price Support on SRPT stock” on October 30, 2016.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.